<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="correction">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Antiviral Res</journal-id>
      <journal-title-group>
        <journal-title>Antiviral Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0166-3542</issn>
      <issn pub-type="epub">1872-9096</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3014095</article-id>
      <article-id pub-id-type="publisher-id">AVR2523</article-id>
      <article-id pub-id-type="doi">10.1016/j.antiviral.2009.07.015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Corrigendum</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Corrigendum to “The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research” [Antiviral Res. 82 (2) (2009) A99–A109]</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Varatharajan</surname>
            <given-names>Lavanya</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>St George's Hospital, Cranmer Terrace, London SW17 ORE, UK</aff>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Thomas</surname>
            <given-names>Sarah A.</given-names>
          </name>
          <email>sarah.thomas@kcl.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="aff2"><label>b</label>King's College London, Pharmaceutical Sciences Research Division, Hodgkin Building, Guy's Campus, London Bridge, London SE1 1UL, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author. Tel.: +44 207 848 6252; fax: +44 207 848 6569. <email>sarah.thomas@kcl.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>11</month>
        <year>2009</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2009</year>
      </pub-date>
      <volume>84</volume>
      <issue>2</issue>
      <fpage>203</fpage>
      <lpage>203</lpage>
      <permissions>
        <copyright-statement>© 2009 Elsevier B.V.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier B.V.</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <related-article related-article-type="corrected-article" id="d30e11" ext-link-type="doi" xlink:href="10.1016/j.antiviral.2008.12.013"/>
    </article-meta>
  </front>
  <body>
    <p>The authors regret that in the production of <xref rid="tbl1" ref-type="table">Table 2</xref> for this paper, information regarding data for ritonavir boosted drugs was omitted. An amended version of <xref rid="tbl1" ref-type="table">Table 2</xref> is now appearing.</p>
    <p>The authors would like to apologise for any inconvenience this may have caused to the authors of this article and the readers of the journal.</p>
  </body>
  <back>
    <ref-list>
      <title>Reference</title>
      <ref id="bib1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Letendre</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Marquie-Beck</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Capparelli</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Best</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Clifford</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Collier</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Gelman</surname>
              <given-names>B.B.</given-names>
            </name>
            <name>
              <surname>McArthur</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>McCutchan</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Morgello</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system</article-title>
          <source>Arch. Neurol.</source>
          <volume>65</volume>
          <year>2008</year>
          <fpage>65</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">18195140</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <table-wrap id="tbl1" position="float">
      <label>Table 2</label>
      <caption>
        <p>A simple scheme to rank CSF-penetrating drugs or the CNS-penetration effectiveness (CPE) ranks, proposed by <xref rid="bib1" ref-type="bibr">Letendre et al. (2008a)</xref>. Rank based on the drug physicochemical characteristics, measured CSF concentrations and CNS efficacy data extracted from publicly available information. Ritonavir boosted = r.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th align="left">Low</th>
            <th align="left">Intermediate</th>
            <th align="left">High</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">NRTIs</td>
            <td align="left">Tenofovir (PMPA)</td>
            <td align="left">Stavudine (d4T)</td>
            <td align="left">Zidovudine (AZT)</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Didanosine (ddI)</td>
            <td align="left">Lamivudine (3TC)</td>
            <td align="left">Abacavir</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Zalcitabine (ddC)</td>
            <td align="left">Emtricitabine (FTC)</td>
            <td/>
          </tr>
          <tr>
            <td colspan="4" align="left">  </td>
          </tr>
          <tr>
            <td align="left">NNRTIs</td>
            <td/>
            <td align="left">Efavirenz</td>
            <td align="left">Delavirdine</td>
          </tr>
          <tr>
            <td/>
            <td/>
            <td/>
            <td align="left">Nevirapine</td>
          </tr>
          <tr>
            <td colspan="4" align="left">  </td>
          </tr>
          <tr>
            <td align="left">PIs</td>
            <td align="left">Nelfinavir</td>
            <td align="left">Amprenavir</td>
            <td align="left">Amprenavir-r</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Ritonavir</td>
            <td align="left">Indinavir</td>
            <td align="left">Indinavir-r</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Saquinavir</td>
            <td align="left">Atazanavir</td>
            <td align="left">Lopinavir-r</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Saquinavir-r</td>
            <td align="left">Atazanavir-r</td>
            <td align="left">Fosamprenavir-r</td>
          </tr>
          <tr>
            <td/>
            <td align="left">Tipranavir-r</td>
            <td align="left">Fosamprenavir</td>
            <td/>
          </tr>
          <tr>
            <td colspan="4" align="left">  </td>
          </tr>
          <tr>
            <td align="left">Fusion inhibitors</td>
            <td align="left">Enfuvirtide</td>
            <td/>
            <td/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>